Welcome to Cato Research

Cato Research is a full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to the people who need them.

» Cato Research Overview | Contact Us

Announcements

  • Cato Research has a new Blog! Visit us often to read timely posts from Cato Research professionals and their guests.

  • Cato Research is now using Twitter! Follow us to keep up to date on the latest Cato news and events.

Recent Posts

  • July 27, 2010 - Generic Lovenox – Moving One Step Closer to Biosimilars – Lovenox is not, I repeat, not a biologic therapeutic. It is derived from a biological source (pig intestines, yum), but it is not protein-based. However, the FDA's approval of a generic form [...]

  • July 26, 2010 - Statistical Implications of Protocol Amendments – Clinical trial protocol amendments occur for good reasons. An unanticipated safety issue may arise, new information about the disease or treatment may suggest alterations, or recruitment and enrollment [...]

  • July 21, 2010 - HHS Proposes Changes to HIPAA – On July 8th, the Department of Health and Human Services (HHS) announced that it was proposing changes to Health Insurance Portability and Accountability Act's (HIPAA's) privacy rules. These changes [...]

  • More Posts...